Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Background: Influenza (flu) is a contagious respiratory illness. It is caused by influenza viruses that infect the nose, throat, and lungs. Some people, such as older people, young children, and people with certain health conditions, are at high risk of serious flu complications. Researchers want to test a vaccine to prevent flu. Objective: To see if the H10 Ferritin vaccine is safe and how the body responds to it. Eligibility: Healthy adults ages 18-70. Design: Participants will be screened with: Medical history Physical exam Blood tests Pregnancy test (if needed). Participants will get 1-2 injections of the study vaccine in the upper arm. They will stay in the clinic for at least 30 minutes after each vaccination. Participants will keep a diary card for 7 days after each vaccination. They will record their temperature and any symptoms. They will measure any skin changes at the injection site. Participants may have nose and throat secretions, and/or oral mucosal samples, collected with a disposable swab. Participants will have blood drawn. Some participants may have apheresis. A needle is placed into a vein in both arms. Blood is removed through a needle in the vein of one arm. The blood is spun in a machine that separates the white blood cells. The rest of the blood is returned to the participant through a needle in the other arm. Before apheresis, participants weight, pulse, and blood pressure will be checked. Their medical history will be taken. Participants will have 8-10 follow-up visits. Participation will last about 10 months.
Description: Occurrence of local reactogenicity signs and symptoms
Measure: Local Reactogenicity Time: 7 days after each product administrationDescription: Occurrence of systemic reactogenicity signs and symptoms
Measure: Systemic Reactogenicity Time: 7 days after each product administrationDescription: Occurrence of laboratory safety measures
Measure: Laboratory measures Time: Day O through 28 days post product administrationDescription: Occurrence of serious adverse events
Measure: Serious adverse events Time: Day O through Day 28ODescription: Occurrence of new-onset of chronic medical conditions
Measure: New chronic medical conditions Time: Day O through Day 28ODescription: Occurrence of unsolicited non-serious adverse events
Measure: Unsolicited adverse events Time: Day O through 28 days post product administrationDescription: Stem-specific antibody responses to HlOssF-6473
Measure: Group 1: vaccine-induced antibodies Time: Day O and 28 days post product administrationDescription: Stem-specific antibody responses to HlOssF-6473
Measure: Group 2A-2B: vaccine-induced antibodies Time: Day O and 2 weeks after each product administrationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports